Interestingly, PAR-1 has also been detected in several types of tumors including melanoma, lung, breast, ovarian, prostate, and gastric cancer [99,100,101,102], and, importantly, its expression levels have been reported to associate with poor prognosis in most of these tumors [99,100,101,102,103]. This evidence concerns the gene F2R and gastric cancer.